TITLE

Detecting DNA damage

AUTHOR(S)
Cairney, Richard
PUB. DATE
August 1998
SOURCE
CMAJ: Canadian Medical Association Journal;08/11/98, Vol. 159 Issue 3, p215
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports that a new technique has been developed to detect genetic mutations. Work of Chris Le et al, University of Alberta, in `Science'; Sensitivity of the test; Implications for the early detection and prevention of cancer; Use of fluorescent antibodies to identify mutations; Ability to base cancer risk on hard data; Ethical concerns.
ACCESSION #
967553

 

Related Articles

  • Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Guertin, Amy D.; Martin, Melissa M.; Roberts, Brian; Hurd, Melissa; Xianlu Qu; Miselis, Nathan R.; Yaping Liu; Jing Li; Feldman, Igor; Benita, Yair; Bloecher, Andrew; Toniatti, Carlo; Shumway, Stuart D. // Cancer Cell International;2012, Vol. 12 Issue 1, p45 

    Background: Inhibition of kinases involved in the DNA damage response sensitizes cells to genotoxic agents by abrogating checkpoint-induced cell cycle arrest. CHK1 and WEE1 act in a pathway upstream of CDK1 to inhibit cell cycle progression in response to damaged DNA. Therapeutic targeting of...

  • Che-1 activates XIAP expression in response to DNA damage. Bruno, T.; Iezzi, S.; De Nicola, F.; Di Padova, M.; Desantis, A.; Scarsella, M.; Di Certo, M. G.; Leonetti, C.; Floridi, A.; Passananti, C.; Fanciulli, M. // Cell Death & Differentiation;Mar2008, Vol. 15 Issue 3, p515 

    X-linked inhibitor of apoptosis protein (XIAP) is a member of the inhibitor of apoptosis proteins family that selectively binds and inhibits caspase-3, -7 and -9. As such, XIAP is an extremely potent suppressor of apoptosis and an attractive target for cancer treatment. Che-1 is an antiapoptotic...

  • Predictive biomarkers for cancer therapy with PARP inhibitors. Michels, J; Vitale, I; Saparbaev, M; Castedo, M; Kroemer, G // Oncogene;7/24/2014, Vol. 33 Issue 30, p3894 

    Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms,...

  • An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Newman, Aaron M; Bratman, Scott V; To, Jacqueline; Wynne, Jacob F; Eclov, Neville C W; Modlin, Leslie A; Liu, Chih Long; Neal, Joel W; Wakelee, Heather A; Merritt, Robert E; Shrager, Joseph B; Loo, Billy W; Alizadeh, Ash A; Diehn, Maximilian // Nature Medicine;May2014, Vol. 20 Issue 5, p548 

    Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient coverage for broad clinical applicability. Here we introduce cancer personalized profiling by deep sequencing...

  • Combining Carefully Selected Drug, Patient Genetics May Lead to Total Tumor Death. Tuma, Rabiya S. // JNCI: Journal of the National Cancer Institute;10/17/2007, Vol. 99 Issue 20, p1505 

    The article examines the effectiveness of synthetic lethal approach on the treatment of cancer. Since neither the drug nor the mutation alone is enough to kill tumor cells, the approach relies on existing mutations in the cancer cells to give drugs extra power. Testing of the approach in cells...

  • Serine/threonine phosphatases in the DNA damage response and cancer. Peng, A; Maller, J L // Oncogene;11/11/2010, Vol. 29 Issue 45, p5977 

    The cellular response to DNA damage is a crucial surveillance mechanism that maintains genomic integrity and prevents cancer progression. Previous studies identified multiple Ser/Thr protein kinases that have pivotal roles in the activation of this response. It is interesting that a growing body...

  • The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment. Sandhu, Shahneen K.; Yap, Timothy A.; de Bono, Johann S. // Current Drug Targets;Dec2011, Vol. 12 Issue 14, p2034 

    Poly(ADP-ribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair via the base excision repair pathway. PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and to also selectively kill homologous recombination repair-defective...

  • TP53 GENE MUTATIONS - FROM GUARDIAN OF THE GENOME TO ONCOGENE. Stojnev, Slavica; Golubović, Mlađan; Babović, Petar // Acta Medica Medianae;Mar2010, Vol. 49 Issue 1, p59 

    TP53 tumor suppressor gene mutations are the most frequent genetic alterations in human cancer affecting a specific gene. The occurrence of TP53 mutations is considerably influenced by cancer-initiating events, such as DNA damage, the aftermath of which is the promotion of cancer development...

  • DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. Pippin, Jeffrey W.; Durvasula, Raghu; Petermann, Arndt; Hiromura, Keiju; Couser, William G.; Shankland, Stuart J. // Journal of Clinical Investigation;3/15/2003, Vol. 111 Issue 6, p877 

    Presents data that a novel consequence of sublytic C5b-9 injury to podocytes is DNA damage. Result of C5b-9-induced injury; Target of immune-mediated injury in glomerular diseases; Reason for the limitation of podocyte proliferation following immune-mediated injury.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics